Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer
Κύριοι συγγραφείς: | Rea, D, Gray, R, Bowden, S, Handley, K, Earl, H, Poole, C, Bates, T, Dewar, J, Raytor, Z, Lee, M |
---|---|
Μορφή: | Conference item |
Έκδοση: |
2013
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study
ανά: Dennis C. Sgroi, κ.ά.
Έκδοση: (2022-12-01) -
An Extraordinary New Toad (Bufo) ttom Costa Rica
ανά: Jay M Savage
Έκδοση: (2002-06-01) -
Tamoxifen-independent recombination in the RIP-CreER mouse.
ανά: Yanmei Liu, κ.ά.
Έκδοση: (2010-10-01) -
Association Between the Gut Microbiota and Blood Pressure in a Population Cohort of 6953 Individuals
ανά: Joonatan Palmu, κ.ά.
Έκδοση: (2020-08-01) -
FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression
ανά: Qing Lv MD, PhD, κ.ά.
Έκδοση: (2021-03-01)